Celldex Therapeutics Q3 EPS $(0.96) Beats $(1.02) Estimate
Benzinga Newsdesk 22 hours ago
NewsEarningsEarnings Beats
Celldex Therapeutics (NASDAQ:CLDX) reported quarterly losses of $(0.96) per share which beat the analyst consensus estimate of $(1.02) by 5.88 percent. This is a 4.95 percent increase over losses of $(1.01) per share
Celldex Therapeutics (NASDAQ:CLDX) reported quarterly losses of $(0.96) per share which beat the analyst consensus estimate of $(1.02) by 5.88 percent. This is a 4.95 percent increase over losses of $(1.01) per share from the same period last year.